JP6799201B2 - エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用 - Google Patents

エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用 Download PDF

Info

Publication number
JP6799201B2
JP6799201B2 JP2016531918A JP2016531918A JP6799201B2 JP 6799201 B2 JP6799201 B2 JP 6799201B2 JP 2016531918 A JP2016531918 A JP 2016531918A JP 2016531918 A JP2016531918 A JP 2016531918A JP 6799201 B2 JP6799201 B2 JP 6799201B2
Authority
JP
Japan
Prior art keywords
salt
imatinib
tyrosine kinase
kinase inhibitor
phenylaminopyrimidine derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016531918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016527275A (ja
JP2016527275A5 (enExample
Inventor
サーバー，マーク，ウイリアム
Original Assignee
アヴァリン ファーマ インク．
アヴァリン ファーマ インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アヴァリン ファーマ インク．, アヴァリン ファーマ インク． filed Critical アヴァリン ファーマ インク．
Publication of JP2016527275A publication Critical patent/JP2016527275A/ja
Publication of JP2016527275A5 publication Critical patent/JP2016527275A5/ja
Application granted granted Critical
Publication of JP6799201B2 publication Critical patent/JP6799201B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
JP2016531918A 2013-07-31 2014-07-31 エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用 Active JP6799201B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361860721P 2013-07-31 2013-07-31
US61/860,721 2013-07-31
US201461948461P 2014-03-05 2014-03-05
US61/948,461 2014-03-05
PCT/US2014/049294 WO2015017728A1 (en) 2013-07-31 2014-07-31 Aerosol tyrosine kinase inhibitor compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018187766A Division JP2019031514A (ja) 2013-07-31 2018-10-02 エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用

Publications (3)

Publication Number Publication Date
JP2016527275A JP2016527275A (ja) 2016-09-08
JP2016527275A5 JP2016527275A5 (enExample) 2017-09-07
JP6799201B2 true JP6799201B2 (ja) 2020-12-16

Family

ID=52432447

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2016531918A Active JP6799201B2 (ja) 2013-07-31 2014-07-31 エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
JP2018187766A Pending JP2019031514A (ja) 2013-07-31 2018-10-02 エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
JP2020030935A Active JP7578258B2 (ja) 2013-07-31 2020-02-26 エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
JP2020162272A Pending JP2021035943A (ja) 2013-07-31 2020-09-28 肺動脈高血圧症（ｐａｈ）の処置のための吸入イマチニブ
JP2022103699A Pending JP2022141677A (ja) 2013-07-31 2022-06-28 エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
JP2022204849A Pending JP2023077426A (ja) 2013-07-31 2022-12-21 エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
JP2024059731A Pending JP2024099535A (ja) 2013-07-31 2024-04-02 エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
JP2024229500A Pending JP2025066712A (ja) 2013-07-31 2024-12-25 エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2018187766A Pending JP2019031514A (ja) 2013-07-31 2018-10-02 エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
JP2020030935A Active JP7578258B2 (ja) 2013-07-31 2020-02-26 エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
JP2020162272A Pending JP2021035943A (ja) 2013-07-31 2020-09-28 肺動脈高血圧症（ｐａｈ）の処置のための吸入イマチニブ
JP2022103699A Pending JP2022141677A (ja) 2013-07-31 2022-06-28 エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
JP2022204849A Pending JP2023077426A (ja) 2013-07-31 2022-12-21 エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
JP2024059731A Pending JP2024099535A (ja) 2013-07-31 2024-04-02 エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
JP2024229500A Pending JP2025066712A (ja) 2013-07-31 2024-12-25 エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用

Country Status (7)

Country Link
US (5) US20150044288A1 (enExample)
EP (2) EP3782604A1 (enExample)
JP (8) JP6799201B2 (enExample)
AU (5) AU2014296032A1 (enExample)
CA (2) CA2919498C (enExample)
ES (1) ES3010397T3 (enExample)
WO (1) WO2015017728A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3007689T3 (en) 2013-01-10 2018-06-14 Pulmokine Inc NON-SELECTIVE KINASE INHIBITORS
AU2014296032A1 (en) * 2013-07-31 2016-03-17 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
JP6483714B2 (ja) 2013-10-11 2019-03-13 ローレンス エス． ジスマン， 噴霧乾燥製剤
CN105664178B (zh) * 2015-09-24 2019-08-20 洪健 Syk作为肝纤维化/硬化治疗靶点的应用
BR112018008503A2 (pt) * 2015-10-26 2018-10-23 Medivation Tech Llc método para tratar câncer de pulmão de células pequenas, método para tratar um sujeito, método para selecionar um sujeito com câncer
US11666656B2 (en) * 2016-02-24 2023-06-06 Ramot At Tel-Aviv University Ltd. Polymeric conjugates and uses thereof
NZ757763A (en) * 2016-03-28 2025-07-25 Presage Biosciences Inc Pharmaceutical combinations for the treatment of cancer
US11278546B2 (en) 2016-07-22 2022-03-22 Aiviva Biopharma, Inc. Multikinase inhibitors and uses in ocular fibrosis
JP2020500183A (ja) 2016-10-27 2020-01-09 プルモキネ、インコーポレイテッド 肺高血圧症の治療のための併用療法
CN110753546B (zh) 2017-04-17 2023-11-10 耶鲁大学 治疗或预防急性肺损伤的化合物、组合物和方法
KR102011375B1 (ko) * 2017-06-30 2019-08-16 주식회사 엠디헬스케어 프로테우스 속 세균 유래 나노소포 및 이의 용도
US11931368B2 (en) * 2017-09-29 2024-03-19 Crititech, Inc. Glucocorticoid “nintedanib” particles and their use
CN109758437A (zh) * 2017-11-09 2019-05-17 北京盈科瑞创新药物研究有限公司 一种雾化吸入用尼达尼布冻干脂质体制剂及其制备方法
TWI866908B (zh) * 2018-04-23 2024-12-21 盈擘生技股份有限公司 用於治療肺部疾病的可吸入的緩釋組成物
WO2019222483A1 (en) 2018-05-17 2019-11-21 Board Of Regents, The University Of Texas System Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors
NZ773615A (en) * 2018-08-22 2025-09-26 Avalyn Pharma Inc Specially formulated compositions of inhaled nintedanib and nintedanib salts
US12497395B2 (en) 2019-04-24 2025-12-16 Convergene, Llc Small molecule bromodomain inhibitors and uses therof
AU2020274521A1 (en) * 2019-05-16 2021-12-16 Aerovate Therapeutics, Inc. Imatinib formulations, manufacture, and uses thereof
US11464776B2 (en) * 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
US20220000767A1 (en) * 2020-07-06 2022-01-06 Sensory Cloud, Inc. Nasal hygiene compositions, antimicrobial treatments, devices, and articles for delivery of same to the nose, trachea and main bronchi
CN116249530A (zh) * 2020-09-14 2023-06-09 伊斯坦布尔大学 具有抗病毒、抗疟疾和/或粘液溶解特性的活性物质通过软雾吸入器或振动网技术雾化器吸入以治疗包括covid-19在内的病毒性肺病中的用途
CA3097717A1 (en) * 2020-11-02 2022-05-02 Skymount Medical Us Inc. Tyrosine kinase in the treatment of coronavirus diseases
WO2022108939A1 (en) 2020-11-17 2022-05-27 United Therapeutics Corporation Inhaled imatinib for pulmonary hypertension field
CN117098557A (zh) * 2020-11-23 2023-11-21 埃渃维特治疗学公司 伊马替尼调配物、其制备和用途
AU2021382051A1 (en) * 2020-11-23 2023-06-08 Aerovate Therapeutics, Inc. Imatinib formulations, manufacture, and uses thereof
AU2022205940A1 (en) * 2021-01-06 2023-07-20 Inaya Therapeutics, Inc. Inhalable imatinib formulation
EP4472609A1 (en) * 2022-02-04 2024-12-11 Justus-Liebig-Universität Gießen Inhaled imatinib for treatment of pulmonary hypertension
US20250127761A1 (en) * 2022-02-10 2025-04-24 Soligenix, Inc. Telmisartan Nanosuspension for Therapy of Respiratory Infections and Methods of Making and Using Same
US20250281512A1 (en) * 2022-04-28 2025-09-11 Know Bio, Llc Buffering agent-containing compositions and methods of using same
CN119677516A (zh) * 2022-05-28 2025-03-21 艾弗林制药有限公司 尼达尼布和尼达尼布组合干粉组合物及用途
EP4554590A1 (en) * 2022-07-13 2025-05-21 Inaya Therapeutics, Inc. Inhalable imatinib formulation
EP4311539A1 (en) * 2022-07-29 2024-01-31 Artorange Ltd. Imatinib formulation for parenteral administration
CN115400082A (zh) * 2022-08-19 2022-11-29 浙江萃泽医药科技有限公司 含铁离子螯合剂的雾化吸入混悬制剂及其制备方法
WO2025157904A1 (en) * 2024-01-24 2025-07-31 Kiox Pharmaceuticals Aps Inhalable formulations of ruxolitinib, methods of manufacture and uses thereof

Family Cites Families (223)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2587215A (en) 1949-04-27 1952-02-26 Frank P Priestly Inhalator
BE555319A (enExample) 1956-03-21 1900-01-01
BE556587A (enExample) 1957-01-31 1957-04-11
US3669113A (en) 1966-03-07 1972-06-13 Fisons Ltd Inhalation device
US3507277A (en) 1966-09-17 1970-04-21 Fisons Pharmaceuticals Ltd Inhalation device
US3456645A (en) 1967-01-19 1969-07-22 Dart Ind Inc Inhalation-actuated aerosol dispensing device
US3456646A (en) 1967-01-19 1969-07-22 Dart Ind Inc Inhalation-actuated aerosol dispensing device
US3456644A (en) 1967-01-19 1969-07-22 Dart Ind Inc Inhalation-actuated aerosol dispensing device
GB1268051A (en) 1968-06-07 1972-03-22 Fisons Pharmaceuticals Ltd Inhalation device
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
US3636949A (en) 1969-08-08 1972-01-25 Armstrong Kropp Dev Corp Inhalation-initiated aerosol dispenser
BE758834A (fr) 1969-11-13 1971-05-12 Riker Laboratoires Inc Distributeur d'aerosol actionne par inhalation
GB1383761A (en) 1971-02-25 1974-02-12 Woodcraft Dc Inhalation device for use with an aerosol container
US3732864A (en) 1971-06-07 1973-05-15 Schering Corp Inhalation coordinated aerosol dispensing device
IT941426B (it) 1971-07-17 1973-03-01 Isf Spa Inalatore a camera di turbinio per sostanze medicamentose polveriformi
US3826255A (en) 1972-06-22 1974-07-30 Hudson Oxygen Therapy Sales Co Intermittent positive pressure breathing manifold
FR2224175B1 (enExample) 1973-04-04 1978-04-14 Isf Spa
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
US3971377A (en) 1974-06-10 1976-07-27 Alza Corporation Medicament dispensing process for inhalation therapy
IT1017153B (it) 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
YU41046B (en) 1974-08-22 1986-10-31 Schering Ag Medicine inholating device
SU628930A1 (ru) 1974-11-26 1978-10-25 Московский научно-исследовательский институт туберкулеза Устройство дл введени порошкообразного лекарственного вещества
US3948264A (en) 1975-05-21 1976-04-06 Mead Johnson & Company Inhalation device
US4147166A (en) 1977-05-02 1979-04-03 American Cyanamid Company Oral inhalator powder dispenser
US4268460A (en) 1977-12-12 1981-05-19 Warner-Lambert Company Nebulizer
US4253468A (en) 1978-08-14 1981-03-03 Steven Lehmbeck Nebulizer attachment
US4263907A (en) 1979-05-14 1981-04-28 Lindsey Joseph W Respirator nebulizer
BR8007911A (pt) 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
SE438261B (sv) 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
US4688218A (en) 1981-07-15 1987-08-18 Etablissement Public De Diffusion Dit "Telediffusion De France" Multiplex channels for continuous flow for numerical signal
US4470412A (en) 1982-03-19 1984-09-11 Trutek Research, Inc. Inhalation valve
US4510929A (en) 1982-04-30 1985-04-16 Bordoni Maurice E Disposable radioactive aerosol inhalation apparatus
US4649911A (en) 1983-09-08 1987-03-17 Baylor College Of Medicine Small particle aerosol generator for treatment of respiratory disease including the lungs
GB8328808D0 (en) 1983-10-28 1983-11-30 Riker Laboratories Inc Inhalation responsive dispensers
US4624251A (en) 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
US4648393A (en) 1984-11-02 1987-03-10 Ackrad Laboratories, Inc. Breath activated medication spray
FR2575678B1 (fr) 1985-01-04 1988-06-03 Saint Gobain Vitrage Ejecteur pneumatique de poudre
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
FI88112C (fi) 1985-07-30 1993-04-13 Glaxo Group Ltd Anordning foer administrering av laekemedel till patienter
US4809692A (en) 1986-01-31 1989-03-07 Trudell Medical Pediatric asthmatic medication inhaler
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
US4790305A (en) 1986-06-23 1988-12-13 The Johns Hopkins University Medication delivery system
US4926852B1 (en) 1986-06-23 1995-05-23 Univ Johns Hopkins Medication delivery system phase one
US5119806A (en) 1987-05-12 1992-06-09 Glaxo Inc. Inhalation device
KR910000142B1 (ko) 1987-05-29 1991-01-21 니혼 다바고 상교오 가부시기가이샤 담배용 필터
US4857311A (en) 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
US4907538A (en) 1988-05-09 1990-03-13 Little Suamico Products Inc. Multiple bin cow feeder
US4832015A (en) 1988-05-19 1989-05-23 Trudell Medical Pediatric asthmatic inhaler
IT1217890B (it) 1988-06-22 1990-03-30 Chiesi Farma Spa Dispositivo per l'inalazione di aerosol dosati
FR2636716B1 (fr) 1988-09-21 1990-12-07 Staubli Sa Ets Dispositif pour l'accouplement des platines porte-elements des raccords multiples
DE68914932T2 (de) 1988-10-04 1994-08-11 Univ Johns Hopkins Inhalationsgerät für Aerosolen.
DK479189D0 (da) 1989-01-06 1989-09-28 Hans Gernot Schenk Inhalator
US5012803A (en) 1989-03-06 1991-05-07 Trudell Medical Modular medication inhaler
US5012804A (en) 1989-03-06 1991-05-07 Trudell Medical Medication inhaler with adult mask
GB8908647D0 (en) 1989-04-17 1989-06-01 Glaxo Group Ltd Device
WO1990013327A1 (en) 1989-04-28 1990-11-15 Riker Laboratories, Inc. Dry powder inhalation device
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
US5152456A (en) 1989-12-12 1992-10-06 Bespak, Plc Dispensing apparatus having a perforate outlet member and a vibrating device
US5113855A (en) 1990-02-14 1992-05-19 Newhouse Michael T Powder inhaler
US5192548A (en) 1990-04-30 1993-03-09 Riker Laboratoires, Inc. Device
GB9015077D0 (en) 1990-07-09 1990-08-29 Riker Laboratories Inc Inhaler
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
IT1243344B (it) 1990-07-16 1994-06-10 Promo Pack Sa Inalatore plurimonodose per medicamenti in polvere
US5060643A (en) 1990-08-07 1991-10-29 Tenax Corporation Breath-activated inhalation device
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
US5217004A (en) 1990-12-13 1993-06-08 Tenax Corporation Inhalation actuated dispensing apparatus
US5040527A (en) 1990-12-18 1991-08-20 Healthscan Products Inc. Metered dose inhalation unit with slide means
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
US5164740A (en) 1991-04-24 1992-11-17 Yehuda Ivri High frequency printing mechanism
AU651882B2 (en) 1991-05-14 1994-08-04 Visiomed Group Limited Aerosol inhalation device
ES2141108T3 (es) 1991-07-02 2000-03-16 Inhale Inc Metodo y dispositivo para proporcionar medicamentos en aerosol.
DE59108798D1 (de) 1991-11-07 1997-08-28 Ritzau Pari Werk Gmbh Paul Vernebler insbesondere zur Anwendung in Geräten für die Inhalationstherapie
JP2849647B2 (ja) 1991-12-04 1999-01-20 ザ テクノロジー パートナーシップ ピーエルシー 流体の小水滴製造装置及びその方法
DE4140689B4 (de) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
DE4142238A1 (de) 1991-12-20 1993-06-24 Boehringer Ingelheim Kg Pulverinhalator mit pulvertraeger aus regelmaessigen mikrostrukturen
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
EP0642366B1 (de) 1992-05-29 1997-10-08 GGU GESELLSCHAFT FÜR GESUNDHEITS- UND UMWELTFORSCHUNG MBH & CO. VERTRIEBS KG Vorrichtung zur erzeugung inhalierbarer wirkstoffpartikel
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5284133A (en) 1992-07-23 1994-02-08 Armstrong Pharmaceuticals, Inc. Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means
NZ250105A (en) 1992-11-09 1996-07-26 Monaghan Canadian Ltd Inhalator mask; one-way valve opens upon exhalation
CA2152088C (en) 1992-12-18 1999-12-07 Thomas J. Ambrosio Inhaler for powdered medications
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US5364838A (en) 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5709202A (en) 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5642730A (en) 1994-06-17 1997-07-01 Trudell Medical Limited Catheter system for delivery of aerosolized medicine for use with pressurized propellant canister
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
EP0810853B1 (en) 1995-02-24 2004-08-25 Elan Pharma International Limited Aerosols containing nanoparticle dispersions
US5586550A (en) 1995-08-31 1996-12-24 Fluid Propulsion Technologies, Inc. Apparatus and methods for the delivery of therapeutic liquids to the respiratory system
US6427682B1 (en) 1995-04-05 2002-08-06 Aerogen, Inc. Methods and apparatus for aerosolizing a substance
US5758637A (en) 1995-08-31 1998-06-02 Aerogen, Inc. Liquid dispensing apparatus and methods
US5921237A (en) 1995-04-24 1999-07-13 Dura Pharmaceuticals, Inc. Dry powder inhaler
US6672304B1 (en) 1995-06-08 2004-01-06 Innovative Devices, Llc Inhalation actuated device for use with metered dose inhalers (MDIs)
CN1325129C (zh) 1995-06-21 2007-07-11 Meda制药有限及两合公司 带整体计量装置的药筒和药粉吸入器
AUPN417395A0 (en) 1995-07-14 1995-08-10 Techbase Pty. Ltd. An improved spacer
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US6209538B1 (en) 1995-08-02 2001-04-03 Robert A. Casper Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament
SE9502799D0 (sv) 1995-08-10 1995-08-10 Astra Ab Device in inhalers
US6026809A (en) 1996-01-25 2000-02-22 Microdose Technologies, Inc. Inhalation device
US5694920A (en) 1996-01-25 1997-12-09 Abrams; Andrew L. Inhalation device
US5823179A (en) 1996-02-13 1998-10-20 1263152 Ontario Inc. Nebulizer apparatus and method
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
FR2747311B1 (fr) 1996-04-10 1998-08-14 Pf Medicament Inhalateur a poudre et a air comprime
US5906202A (en) 1996-11-21 1999-05-25 Aradigm Corporation Device and method for directing aerosolized mist to a specific area of the respiratory tract
US6349719B2 (en) 1997-02-24 2002-02-26 Aradigm Corporation Formulation and devices for monitoring the efficacy of the delivery of aerosols
US6006747A (en) 1997-03-20 1999-12-28 Dura Pharmaceuticals, Inc. Dry powder inhaler
DE19713636A1 (de) 1997-04-02 1998-10-08 Pari Gmbh Atemzugsimulator
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US5855564A (en) 1997-08-20 1999-01-05 Aradigm Corporation Aerosol extrusion mechanism
US6293279B1 (en) 1997-09-26 2001-09-25 Trudell Medical International Aerosol medication delivery apparatus and system
EP1021172B1 (en) 1997-10-08 2002-04-10 Sepracor, Inc. Dosage form for aerosol administration
US6003512A (en) 1997-11-13 1999-12-21 Lovelace Respiratory Research Institute Dust gun-aerosol generator and generation
EP1129741B1 (en) 1997-11-19 2006-04-12 Microflow Engineering SA Spray device for an inhaler
US6192876B1 (en) 1997-12-12 2001-02-27 Astra Aktiebolag Inhalation apparatus and method
US6223746B1 (en) 1998-02-12 2001-05-01 Iep Pharmaceutical Devices Inc. Metered dose inhaler pump
US6026807A (en) 1998-02-27 2000-02-22 Diemolding Corporation Metered dose inhaler cloud chamber
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
US6585958B1 (en) 1998-07-24 2003-07-01 Jago Research Ag Medicinal aerosol formulations
HRP20010119B1 (hr) 1998-08-18 2008-05-31 The Regents Of The University Of California Sprječavanje stvaranja sluzi u dišnim putevima primjenom antagonista egf-r
GB2343122B (en) 1998-10-26 2003-01-08 Medic Aid Ltd Improvements in and relating to nebulisers
US6070575A (en) 1998-11-16 2000-06-06 Aradigm Corporation Aerosol-forming porous membrane with certain pore structure
US6861442B1 (en) 1998-12-30 2005-03-01 Sugen, Inc. PYK2 and inflammation
US6584971B1 (en) 1999-01-04 2003-07-01 Medic-Aid Limited Drug delivery apparatus
US6338443B1 (en) 1999-06-18 2002-01-15 Mercury Enterprises, Inc. High efficiency medical nebulizer
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
EP1666028B1 (en) 1999-10-29 2010-03-24 Novartis AG Dry powder compositions having improved dispersivity
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
WO2001076671A2 (en) 2000-04-11 2001-10-18 Trudell Medical International Aerosol delivery apparatus with positive expiratory pressure capacity
PL209733B1 (pl) 2000-10-27 2011-10-31 Novartis Ag Zastosowanie 4-(4-metylopiperazyno-1-ylometylo)-N-[4-metylo-3-(4-pirydyn-3-ylo)pirymidyn-2-yloamino)fenylo]benzamidu w leczeniu żołądkowo-jelitowych guzów podścieliskowych
US6601581B1 (en) 2000-11-01 2003-08-05 Advanced Medical Applications, Inc. Method and device for ultrasound drug delivery
US6626173B2 (en) 2001-01-08 2003-09-30 Iep Pharmaceutical Devices Inc. Dry powder inhaler
DE10102846B4 (de) 2001-01-23 2012-04-12 Pari Pharma Gmbh Aerosolgenerator
US6523536B2 (en) 2001-03-12 2003-02-25 Birdsong Medical Devices, Inc. Dual-canister inhaler having a spacer and easy to operate lever mechanism
US6681768B2 (en) 2001-06-22 2004-01-27 Sofotec Gmbh & Co. Kg Powder formulation disintegrating system and method for dry powder inhalers
ES2274993T3 (es) 2001-06-29 2007-06-01 Ab Science Utilizacion de inhibidores de tirosina cinasa para el tratamiento de enfermedades alergicas.
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
WO2003026797A2 (en) 2001-09-21 2003-04-03 Solvias Ag Sealing system with flow channels
EP1304131B1 (de) 2001-10-18 2005-06-29 PARI GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
EP1304130B1 (de) 2001-10-18 2004-06-23 PARI GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
EP1438019A1 (en) 2001-10-24 2004-07-21 PARI GmbH Spezialisten für effektive Inhalation Kit for the preparation of a pharmaceutical composition
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
CA2485340C (en) 2002-05-07 2015-09-29 The State University Of New York At Stony Brook Methods, devices and formulations for targeted endobronchial therapy
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
DE10233500A1 (de) 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
GB2398565A (en) 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
US20060234931A1 (en) 2003-07-17 2006-10-19 Biggs William H Iii Treatment of diseases with kinase inhibitors
KR20120073370A (ko) 2003-09-17 2012-07-04 넥타르 테라퓨틱스 다분지형 고분자 전구약물
JP5520433B2 (ja) 2004-01-21 2014-06-11 エモリー ユニバーシティー 病原体感染を処置するためのチロシンキナーゼインヒビターの組成物および使用
MY144177A (en) 2004-02-04 2011-08-15 Novartis Ag Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide.
JP2008514576A (ja) 2004-09-27 2008-05-08 アストラゼネカ アクチボラグ Ａｚｄ２１７１およびイマチニブを含む癌組合せ療法
MX2007003505A (es) 2004-09-27 2007-05-10 Astrazeneca Ab Combinacion que comprende zd6474 e imatinib.
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1833815B1 (en) 2004-12-30 2010-09-15 Instytut Farmaceutyczny A process for preparation of imatinib base
US7507821B2 (en) 2004-12-30 2009-03-24 Chemagis Ltd. Process for preparing Imatinib
US8524735B2 (en) * 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
WO2006125132A2 (en) 2005-05-18 2006-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
CN101232870A (zh) 2005-06-03 2008-07-30 伊兰制药国际有限公司 纳米微粒甲磺酸伊马替尼制剂
DE602006021312D1 (de) 2005-06-09 2011-05-26 Bristol Myers Squibb Co Pharmazeutische zusammensetzung zur anwendung in der behandlung von personen mit mutant-kit-protein
WO2007050783A2 (en) 2005-10-26 2007-05-03 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
CA2626326C (en) 2005-11-04 2021-02-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
EP1968579A1 (en) 2005-12-30 2008-09-17 Astex Therapeutics Limited Pharmaceutical compounds
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
MXPA06007070A (es) 2006-03-24 2007-09-24 Univ Kyushu Compuestos organicos.
DE102006017699A1 (de) 2006-04-15 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalator
US20060223817A1 (en) 2006-05-15 2006-10-05 Chemagis Ltd. Crystalline imatinib base and production process therefor
EP1870400A1 (en) 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
US20080181958A1 (en) 2006-06-19 2008-07-31 Rothrock Ginger D Nanoparticle fabrication methods, systems, and materials
US20080066739A1 (en) * 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
WO2008039941A2 (en) 2006-09-27 2008-04-03 The Government Of The Usa As Represented By The Secretary Of The Dpt. Of Health And Human Services Scgb3a2 as a growth factor and anti-apoptotic agent
EP2076507A2 (en) 2006-10-26 2009-07-08 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
WO2008136010A1 (en) 2007-05-07 2008-11-13 Natco Pharma Limited A process for the preparation of highly pure imatinib base
EP2170270B1 (en) 2007-06-05 2016-01-13 Paka Pulmonary Pharmaceuticals, Inc. Compositions for delivering medicaments into the lungs, uses thereof
ES2391625T3 (es) 2007-06-07 2012-11-28 Novartis Ag Formas amorfas estabilizadas de mestilato de imatinib
WO2008152014A2 (en) 2007-06-12 2008-12-18 Boehringer Ingelheim International Gmbh 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases
KR101553723B1 (ko) * 2007-07-13 2015-09-16 네스텍 소시에테아노님 항체­기반 어레이를 사용한 폐 암 치료를 위한 약물 선별법
EP2062885A1 (en) 2007-11-21 2009-05-27 Eczacibasi-Zentiva Kimyasal Ürünler Sanayi ve Ticaret A.S. Acid addition salts of imatinib and formulations comprising the same
UY31506A1 (es) 2007-12-03 2009-08-03 Derivados de indolinona y procedimiento para su preparacion
US8008445B2 (en) 2008-03-03 2011-08-30 Dyax Corp. Metalloproteinase 9 binding proteins
EP2098219A1 (en) * 2008-03-05 2009-09-09 PARI Pharma GmbH Macrolide compositions having improved taste and stability
EP2985025B1 (en) 2008-06-06 2018-01-17 Boehringer Ingelheim International Gmbh Pharmaceutical combination
EP2299987B1 (en) 2008-06-06 2018-02-21 Boehringer Ingelheim International GmbH Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
UA107560C2 (uk) 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
EP2315592A1 (en) * 2008-08-13 2011-05-04 Novartis AG Treatment of pulmonary arterial hypertension
US8802384B2 (en) 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
US20100330130A1 (en) 2009-05-22 2010-12-30 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
WO2011039782A1 (en) 2009-09-29 2011-04-07 Ind-Swift Laboratories Limited Processes for preparing imatinib and pharmaceutically acceptable salts thereof
EP2509973A1 (en) 2009-12-10 2012-10-17 Arch Pharmalabs Limited Process for the preparation of imatinib and salts thereof
US20110183948A1 (en) 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
WO2011095835A1 (en) 2010-02-02 2011-08-11 Actavis Group Ptc Ehf Highly pure imatinib or a pharmaceutically acceptable salt thereof
WO2011100282A2 (en) 2010-02-09 2011-08-18 Dr. Reddy's Laboratories Ltd. Imatinib mesylate polymorphs
EP2547671A1 (en) 2010-03-15 2013-01-23 Natco Pharma Limited Process for the preparation of highly pure crystalline imatinib base
EP2582689B1 (en) * 2010-06-18 2017-03-01 KRKA, D.D., Novo Mesto New polymorphic form of imatinib base and preparation of salts thereof
WO2012090221A1 (en) * 2010-12-29 2012-07-05 Cadila Healthcare Limited Novel salts of imatinib
US8691777B2 (en) 2011-01-27 2014-04-08 Emory University Combination therapy
DK2670242T3 (da) * 2011-01-31 2022-05-02 Avalyn Pharma Inc Aerosolpirfenidon- og pyridonanalogforbindelser og anvendelser deraf
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
AU2012258575B2 (en) * 2011-05-25 2017-03-02 Intermune, Inc. Pirfenidone and anti-fibrotic therapy in selected patients
EP2756840B1 (en) * 2011-09-14 2020-08-19 Shionogi & Co., Ltd. Pharmaceutical composition for inhalation
ES2639338T3 (es) 2012-01-25 2017-10-26 Bayer Pharma Aktiengesellschaft Fenilimidazopirazoles sustituidos y su uso
RU2014139546A (ru) 2012-03-27 2016-05-20 Дженентек, Инк. Методы прогнозирования, диагностики и лечения идиопатического легочного фиброза
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
ES2959198T3 (es) 2012-07-24 2024-02-21 Avalyn Pharma Inc Compuestos análogos de pirfenidona y piridona en aerosol
DK3007689T3 (en) * 2013-01-10 2018-06-14 Pulmokine Inc NON-SELECTIVE KINASE INHIBITORS
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
AU2014296032A1 (en) 2013-07-31 2016-03-17 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
AU2015204558B2 (en) 2014-01-10 2020-04-30 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US20200069679A1 (en) 2016-12-12 2020-03-05 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with oladaterol
NZ773615A (en) * 2018-08-22 2025-09-26 Avalyn Pharma Inc Specially formulated compositions of inhaled nintedanib and nintedanib salts
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
AU2020274521A1 (en) 2019-05-16 2021-12-16 Aerovate Therapeutics, Inc. Imatinib formulations, manufacture, and uses thereof

Also Published As

Publication number Publication date
AU2014296032A1 (en) 2016-03-17
US20150044288A1 (en) 2015-02-12
JP7578258B2 (ja) 2024-11-06
CA2919498A1 (en) 2015-02-05
JP2016527275A (ja) 2016-09-08
JP2021035943A (ja) 2021-03-04
ES3010397T3 (en) 2025-04-02
US20210093570A1 (en) 2021-04-01
CA2919498C (en) 2023-07-25
AU2018222878A1 (en) 2018-09-13
AU2020201933A1 (en) 2020-04-09
CA3172586C (en) 2025-10-14
US20220087937A1 (en) 2022-03-24
US20210093569A1 (en) 2021-04-01
JP2019031514A (ja) 2019-02-28
EP3027026C0 (en) 2024-11-13
JP2025066712A (ja) 2025-04-23
AU2024203957A1 (en) 2024-07-04
EP3027026A4 (en) 2017-05-03
US20250090463A1 (en) 2025-03-20
WO2015017728A1 (en) 2015-02-05
AU2022202349A1 (en) 2022-04-28
CA3172586A1 (en) 2015-02-05
NZ717528A (en) 2024-07-05
EP3782604A1 (en) 2021-02-24
JP2023077426A (ja) 2023-06-05
EP3027026A1 (en) 2016-06-08
JP2024099535A (ja) 2024-07-25
JP2022141677A (ja) 2022-09-29
US11980689B2 (en) 2024-05-14
JP2020111576A (ja) 2020-07-27
EP3027026B1 (en) 2024-11-13

Similar Documents

Publication Publication Date Title
JP7578258B2 (ja) エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
US12023342B2 (en) Aerosol pirfenidone and pyridone analog compounds and uses thereof
US11559520B2 (en) Aerosol pirfenidone and pyridone analog compounds and uses thereof
JP2024095678A (ja) エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
US20250367178A1 (en) Aerosol pirfenidone and pyridone analog compounds and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200417

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200511

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20200610

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201019

R150 Certificate of patent or registration of utility model

Ref document number: 6799201

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250